ZOMIG-ZMT Drug Patent Profile
✉ Email this page to a colleague
When do Zomig-zmt patents expire, and what generic alternatives are available?
Zomig-zmt is a drug marketed by Astrazeneca and is included in one NDA.
The generic ingredient in ZOMIG-ZMT is zolmitriptan. There are twenty drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the zolmitriptan profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Zomig-zmt
A generic version of ZOMIG-ZMT was approved as zolmitriptan by GLENMARK PHARMS LTD on May 14th, 2013.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ZOMIG-ZMT?
- What are the global sales for ZOMIG-ZMT?
- What is Average Wholesale Price for ZOMIG-ZMT?
Summary for ZOMIG-ZMT
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 99 |
Patent Applications: | 4,436 |
DailyMed Link: | ZOMIG-ZMT at DailyMed |
US Patents and Regulatory Information for ZOMIG-ZMT
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Astrazeneca | ZOMIG-ZMT | zolmitriptan | TABLET, ORALLY DISINTEGRATING;ORAL | 021231-001 | Feb 13, 2001 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Astrazeneca | ZOMIG-ZMT | zolmitriptan | TABLET, ORALLY DISINTEGRATING;ORAL | 021231-002 | Sep 17, 2001 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ZOMIG-ZMT
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Astrazeneca | ZOMIG-ZMT | zolmitriptan | TABLET, ORALLY DISINTEGRATING;ORAL | 021231-001 | Feb 13, 2001 | ⤷ Sign Up | ⤷ Sign Up |
Astrazeneca | ZOMIG-ZMT | zolmitriptan | TABLET, ORALLY DISINTEGRATING;ORAL | 021231-002 | Sep 17, 2001 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ZOMIG-ZMT
See the table below for patents covering ZOMIG-ZMT around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Germany | 69132691 | ⤷ Sign Up | |
Denmark | 0486666 | ⤷ Sign Up | |
Hungary | 211479 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ZOMIG-ZMT
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0486666 | SPC/GB97/089 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: ZOLMITRIPTAN AND OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK 12619/0116 19970307 |
0486666 | C980001 | Netherlands | ⤷ Sign Up | PRODUCT NAME: ZOLMITRIPTANUM, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH AANVAARDBAAR ZOUT OF VAN EEN SOLVAAT; NAT. REGISTRATION NO/DATE: RVG 21079, RVG 21080 19970925; FIRST REGISTRATION: GB PL 12619/0116 19970307 |
0463756 | 300048 | Netherlands | ⤷ Sign Up | PRODUCT NAME: ZOLMITRIPTANUM, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH AANVAARDBAAR ZOUT OF VAN EEN SOLVAAT; NATL. REGISTRATION: RVG 21079 RVG 21080 19970925; FIRST REGISTRATION: PL 12619/0116 19970307 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |